

09/355,214

WEST

Help

Logout

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Generate Collection

Search Results - Record(s) 1 through 7 of 7 returned.☐ 1. Document ID: US 6004811 A

Entry 1 of 7

File: USPT

Dec 21, 1999

US-PAT-NO: 6004811

DOCUMENT-IDENTIFIER: US 6004811 A

TITLE: Redirection of cellular immunity by protein tyrosine kinase chimeras

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seed, Brian	Boston	MA	N/A	N/A
Romeo, Charles	Belmont	MA	N/A	N/A
Kolanus, Waldemar	Watertown	MA	N/A	N/A

US-CL-CURRENT: 435/372.3; 435/375, 435/6, 435/69.1, 536/23.4, 536/23.5

ABSTRACT:

Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are calls which express the chimeric receptors and DNA encoding the chimeric receptors.

23 Claims, 19 Drawing figures

Exemplary Claim Number: 1,5

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 2. Document ID: US 6001839 A

Entry 2 of 7

File: USPT

Dec 14, 1999

US-PAT-NO: 6001839
DOCUMENT-IDENTIFIER: US 6001839 A

TITLE: Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Calderwood; David J.	Nottingham	N/A	N/A	GBX
Johnston; David N.	Nottingham	N/A	N/A	GBX
Rafferty; Paul	Nottingham	N/A	N/A	GBX
Twigger; Helen L.	Nottingham	N/A	N/A	GBX
Munschauer; Rainer	Shrewsbury	MA	N/A	N/A
Arnold; Lee	Westborough	MA	N/A	N/A

US-CL-CURRENT: 514/258; 544/280

ABSTRACT:

Compounds of formula I ##STR1## including pharmaceutically acceptable salts thereof in which R.sub.1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, a C.sub.5-7 cycloalkenyl group or an (optionally substituted phenyl)C.sub.1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula OR.sub.A in which R.sub.A represents H or a C.sub.1-6 alkyl group provided that a group of formula OR.sub.A is not located on the carbon attached to nitrogen;

R.sub.2 represents hydrogen, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C.sub.1-6 alkyl group, optionally substituted phenyl or R.sub.4 ; and

R.sub.3 represents a group of formula (a) ##STR2## in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO.sub.2, SO.sub.2 NH, a C.sub.1-4 alkylene chain, NHCO, NHCO.sub.2, CONH, NHCONH, CO.sub.2 or S(O).sub.p in which p is 0, 1 or 2, or A is absent and R.sub.5 is attached directly to the phenyl ring;

and R.sub.5 represents optionally substituted phenyl and, additionally, when A is absent R.sub.5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl;

R.sub.4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.

28 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 3. Document ID: US 5912170 A

Entry 3 of 7

File: USPT

Jun 15, 1999

US-PAT-NO: 5912170
DOCUMENT-IDENTIFIER: US 5912170 A

TITLE: Redirection of cellular immunity by protein-tyrosine kinase chimeras

DATE-ISSUED: June 15, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seed; Brian	Boston	MA	N/A	N/A
Romeo; Charles	Belmont	MA	N/A	N/A
Kolanus; Waldemar	Watertown	MA	N/A	N/A

US-CL-CURRENT: 435/325; 435/352, 435/354, 435/366

ABSTRACT:

Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.

20 Claims, 19 Drawing figures

Exemplary Claim Number: 1,4

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 4. Document ID: US 5801149 A

Entry 4 of 7

File: USPT

Sep 1, 1998

US-PAT-NO: 5801149

DOCUMENT-IDENTIFIER: US 5801149 A

TITLE: Inhibition of signal transduction molecules

DATE-ISSUED: September 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shoelson; Steven	Natick	MA	N/A	N/A

US-CL-CURRENT: 514/18; 514/13, 514/14, 514/15, 514/16, 514/17, 514/324, 514/325, 530/330

ABSTRACT:

A peptide capable of inhibiting the interaction of an SH2 domain containing protein with a second protein.

16 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 5. Document ID: US 5786488 A

Entry 5 of 7

File: USPT

Jul 28, 1998

US-PAT-NO: 5786488
DOCUMENT-IDENTIFIER: US 5786488 A

TITLE: Synthetic methods for the preparation of indolyquinones

DATE-ISSUED: July 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tang; Peng C.	Moraga	CA	N/A	N/A
Harris; G. Davis	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 548/455; 548/460, 548/469, 548/492, 548/494

ABSTRACT:

The present invention relates to novel synthetic methods for the preparation of indolyquinones. The methods of the present invention are directed to synthetic reactions involving indoles and halo-quinones in solvent and in the presence of a metal carbonate. The invention also relates to bis- and mono-indolyquinones of high purity and pharmaceutical compositions containing the same.
30 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

☐ 6. Document ID: US 5780496 A

Entry 6 of 7

File: USPT

Jul 14, 1998

US-PAT-NO: 5780496
DOCUMENT-IDENTIFIER: US 5780496 A

TITLE: Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tang; Peng Cho	Moraga	CA	N/A	N/A
McMahon; Gerald	San Francisco	CA	N/A	N/A
Harris; G. Davis	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 514/414; 548/455

ABSTRACT:

The present invention relates to methods and compositions for the inhibition of adaptor protein/protein tyrosine kinase protein interactions, especially wherein those interactions involving a protein tyrosine kinase capable of completing with a member of the SH2- and/or SH3-containing family of adaptor proteins are associated with a cell proliferative disorder. Specifically, the present invention relates to particular compounds, especially quinazoline derivative compounds, and methods utilizing such compounds.
27 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

☐ 7. Document ID: US 5667981 A

Entry 7 of 7

File: USPT

Sep 16, 1997

US-PAT-NO: 5667981
DOCUMENT-IDENTIFIER: US 5667981 A

TITLE: Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein

DATE-ISSUED: September 16, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Groffen; John H.	Los Angeles	CA	N/A	N/A
Heisterkamp; Nora C.	Los Angeles	CA	N/A	N/A
Hoeve; Johanna Ten	Los Angeles	CA	N/A	N/A

US-CL-CURRENT: 435/7.23; 435/7.24, 436/63, 436/64, 436/813

ABSTRACT:

The invention relates to methods and kits for diagnosing cancers arising from cells which express tyrosine phosphorylated CRKL protein, such as cells having the Philadelphia (Ph) chromosome, which includes chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), through the detection of increased levels of phosphorylated CRKL protein or through the detection of increased CRKL gene copy or mRNA expression. The invention also relates to methods of treating such cancers.

20 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Generate Collection

Terms	Documents
15 not 16	7

Display 10 Documents

including document number

7

Display Format:

REV

Change Format

Main Menu	Search Form	Posting Counts	Show S Numbers	Edit S Numbers
-----------	-------------	----------------	----------------	----------------

Help

Logout

WEST[Help](#)[Logout](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)**Search Results -**

Terms	Documents
15 not 16	7

Database:

Refine Search:

Search History

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	15 not 16	7	<u>L8</u>
USPT	slp76	0	<u>L7</u>
USPT	15 and screen	16	<u>L6</u>
USPT	bcr and ptk	23	<u>L5</u>
USPT	bcr and drug near screen	3	<u>L4</u>
USPT	bcr same drug near screen	0	<u>L3</u>
USPT	brc same drug near screen	0	<u>L2</u>
USPT	brc same ligand	0	<u>L1</u>

WEST[Help](#)[Logout](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Generate Collection](#)**Search Results - Record(s) 1 through 10 of 16 returned.**☐ 1. Document ID: US 6037134 A

Entry 1 of 16

File: USPT

Mar 14, 2000

US-PAT-NO: 6037134

DOCUMENT-IDENTIFIER: US 6037134 A

TITLE: Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes

DATE-ISSUED: March 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Margolis; Benjamin Lewis	New York	NY	N/A	N/A

US-CL-CURRENT: 435/7.23; 435/7.1, 436/63, 436/64

ABSTRACT:

The present invention relates to compositions and methods for the prevention, prognostic evaluation, and treatment of oncogenic disorders, especially breast cancer, wherein a protein tyrosine kinase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. In a preferred embodiment of the invention, the protein tyrosine kinase is the receptor protein tyrosine kinase HER2, and the adaptor protein is GRB, so that the protein tyrosine kinase/adaptor protein complex is a HER2/GRB-7 complex.

10 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 2. Document ID: US 6001583 A

Entry 2 of 16

File: USPT

Dec 14, 1999

US-PAT-NO: 6001583

DOCUMENT-IDENTIFIER: US 6001583 A

TITLE: Methods for disrupting GRB-7 complexes

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Margolis; Benjamin Lewis	New York	NY	N/A	N/A

US-CL-CURRENT: 435/7.23; 424/138.1, 424/143.1, 436/64, 514/2

ABSTRACT:

The present invention relates to compositions and methods for the prevention, prognostic evaluation, and treatment of oncogenic disorders, especially breast cancer, wherein a protein tyrosine kinase capable of complexing with a member of the SH2-and/or SH3-containing family of adaptor proteins is involved. In a preferred embodiment of the invention, the protein tyrosine kinase is the receptor protein tyrosine kinase HER2 or SHC polypeptide, and the adaptor protein is GRB-7, so that the protein tyrosine kinase/adaptor protein complex is a HER2/GRB-7 complex or a SHC/GRB-7 complex.

5 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 3. Document ID: US 5998596 A

Entry 3 of 16

File: USPT

Dec 7, 1999

US-PAT-NO: 5998596

DOCUMENT-IDENTIFIER: US 5998596 A

TITLE: Inhibition of protein kinase activity by aptameric action of oligonucleotides

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bergan; Raymond	Rockville	MD	N/A	N/A
Neckers; Len	Bethesda	MD	N/A	N/A

US-CL-CURRENT: 536/22.1; 536/23.1, 536/24.3

ABSTRACT:

The present invention are oligonucleotides that specifically bind to and directly inhibit the biological function of target molecules such as proteins, peptides or derivatives. The direct or aptameric interaction of oligonucleotides of the present invention with proteins, peptides and derivatives represents a non-antisense mediated effect. The oligonucleotides have been shown to bind to isolated target molecules and to inhibit biological function of the target molecule within cells. In particular, the oligonucleotides have been shown to directly inhibit the kinase activity of protein-tyrosine kinase. The oligonucleotides of the present invention have significant beneficial effects against a chronic myelogenous leukemia derived cell line as demonstrated using cellular phosphotyrosine content as well as cellular growth in soft agar.

12 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 4. Document ID: US 5994522 A

Entry 4 of 16

File: USPT

Nov 30, 1999

US-PAT-NO: 5994522

DOCUMENT-IDENTIFIER: US 5994522 A

TITLE: BLNK proteins

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chan; Andrew C.	St. Louis	MO	N/A	N/A
Fu; Chong	St. Louis	MO	N/A	N/A

US-CL-CURRENT: 536/23.5; 435/252.3, 435/320.1, 435/325, 435/366

ABSTRACT:

The invention relates to novel BLNK proteins, nucleic acids and antibodies.
7 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 5. Document ID: US 5962224 A

Entry 5 of 16

File: USPT

Oct 5, 1999

US-PAT-NO: 5962224

DOCUMENT-IDENTIFIER: US 5962224 A

TITLE: Isolated DNA encoding p62 polypeptides and uses therefor

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shin; Jaekyoon	Westwood	MA	N/A	N/A
Joung; Insil	Boston	MA	N/A	N/A
Vadlamudi; Ratna K.	Norwood	MA	N/A	N/A
Strominger; Jack L.	Lexington	MA	N/A	N/A

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/366, 435/69.1, 435/70.1, 536/23.1, 536/24.31, 536/24.33

ABSTRACT:

Isolated nucleic acid molecules encoding novel members of the p62 family of polypeptides which include, in preferred embodiment, an SH2 binding domain and a ubiquitin binding domain are described. Also disclosed are novel members of the p160 family of polypeptides. The p62 polypeptides and the p160 polypeptides of the invention are capable of modulating leukocyte activity, e.g., by stimulating a B cell response, including B cell proliferation, B cell aggregation, B cell differentiation, B cell survival, and/or stimulating a T cell response, e.g., T cell proliferation, T cell aggregation, T cell differentiation, and T cell survival, are disclosed. The p62 polypeptides and the p160 polypeptides of the invention are also capable of modulating ubiquitin-mediated degradation of cellular proteins. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated p62

introduced are also described. The invention further provides isolated p62 polypeptides and isolated p160 polypeptides, fusion polypeptides and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

28 Claims, 32 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 52

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 6. Document ID: US 5951979 A

Entry 6 of 16

File: USPT

Sep 14, 1999

US-PAT-NO: 5951979

DOCUMENT-IDENTIFIER: US 5951979 A

TITLE: Substrate trapping protein tyrosine phosphatases

DATE-ISSUED: September 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tonks; Nicholas	Huntington	NY	N/A	N/A
Flint; Andrew J.	Bothell	WA	N/A	N/A

US-CL-CURRENT: 424/94.6; 435/196

ABSTRACT:

Novel protein tyrosine phosphatases in which the invariant aspartate residue is replaced with an alanine residue and which bind to a tyrosine phosphorylated substrate and are catalytically attenuated are described. Also described are methods of identifying tyrosine phosphorylated proteins which complex with the described protein tyrosine phosphatases.

8 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 7. Document ID: US 5912138 A

Entry 7 of 16

File: USPT

Jun 15, 1999

US-PAT-NO: 5912138

DOCUMENT-IDENTIFIER: US 5912138 A

TITLE: Substrate trapping protein tyrosine phosphatases

DATE-ISSUED: June 15, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tonks; Nicholas	Huntington	NY	N/A	N/A
Flint; Andrew J.	Bothell	WA	N/A	N/A

US-CL-CURRENT: 435/21; 435/196

ABSTRACT:

Novel protein tyrosine phosphatases in which the invariant aspartate residue is replaced with an alanine residue and which bind to a tyrosine phosphorylated substrate and are catalytically attenuated are described. Also described are methods of identifying tyrosine phosphorylated proteins which complex with the described protein tyrosine phosphatases.

21 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 8. Document ID: US 5776902 A

Entry 8 of 16

File: USPT

Jul 7, 1998

US-PAT-NO: 5776902

DOCUMENT-IDENTIFIER: US 5776902 A

TITLE: Boronophenyl analogs of phosphotyrosines

DATE-ISSUED: July 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bachovchin; William W.	Melrose	MA	N/A	N/A

US-CL-CURRENT: 514/18; 514/19, 530/330, 530/331, 556/7, 564/152, 564/153

ABSTRACT:

The present invention makes available novel compounds useful for inhibiting kinases, phosphatases and SH2 domains, e.g., an interaction between a protein containing an SH2 domain and a phosphotyrosine-containing polypeptide. In one embodiment, the present invention provides boronylphenyl analogs of phosphotyrosines which, in such forms as peptidomimetics, can be used to modulate signal transduction pathways in cells.

15 Claims, 21 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 9. Document ID: US 5770421 A

Entry 9 of 16

File: USPT

Jun 23, 1998

US-PAT-NO: 5770421
DOCUMENT-IDENTIFIER: US 5770421 A

TITLE: Human ALK protein tyrosine kinase

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morris; Stephan W.	Memphis	TN	N/A	N/A
Look; A. Thomas	Memphis	TN	N/A	N/A

US-CL-CURRENT: 435/194; 530/324, 530/350, 530/352, 530/358

ABSTRACT:

The present invention is based on the identification and sequence determination of a novel gene, ALK, which is fused to the gene encoding nucleophosmin (NPM) in translocations present in t(2;5) lymphoma cells. Based on homologies to other proteins, the amino acid sequence of the polypeptide encoded by the ALK (Anaplastic Lymphoma Kinase) gene is a membrane-spanning protein tyrosine kinase (PTK)/receptor. Antibodies to the ALK PTK/receptor and methods utilizing such antibodies are described, as are methods of using the ALK gene to isolate ligands for the ALK PTK/receptor.

12 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 10. Document ID: US 5741689 A

Entry 10 of 16

File: USPT

Apr 21, 1998

US-PAT-NO: 5741689
DOCUMENT-IDENTIFIER: US 5741689 A

TITLE: Methods to inhibit serine kinase activity and to alter intersubunit binding activity of phosphatidylinositol 3-kinase, and serine kinase active sequence of the same

DATE-ISSUED: April 21, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dhand; Ritu Bala	London	N/A	N/A	GB2
Waterfield; Michael Derek	Speen Newbury	N/A	N/A	GB2
Hiles; Ian Donald	Bromley	N/A	N/A	GB2
Gout; Ivan Tarasovich	London	N/A	N/A	GB2
Kasuga; Masato	Kobe	N/A	N/A	JPX
Yonezawa; Kazuyoshi	Kobe	N/A	N/A	JPX
End; Peter	London	N/A	N/A	GB2
Fry; Michael	London	N/A	N/A	GB2
Panayotou; George	London	N/A	N/A	GB2

US-CL-CURRENT: 435/194; 424/139.1, 435/252.3, 435/320.1, 435/331, 435/338, 536/23.1, 536/24.1

ABSTRACT:

The invention provides for a method to inhibit the binding between the p85 and p110 subunits of said PI3-kinase and thus a method to modulate PI3-kinase activity and modulate the response of cells to external stimuli. In particular, disabling, by conventional means, residues located in the inter-SH2 domain of said p85 subunit, specifically a region containing amino acid residue 478 to amino acid residue 513 of p85.alpha. subunit, or amino acid residue 445 to amino acid residue 485 of p85.beta. subunit of said PI3-kinase. Interference with these binding regions will affect binding between the subunits and results in inhibiting PI3-kinase activity. This invention further relates to a methods to modulate the serine kinase activity of the PI3-kinase which can be achieved by disabling the DRHNSN sequence of the p110 subunit and can also be used to effect changes in overall PI3-kinase activity. This invention is further related to an (ant)agonist which affects serine kinase activity of PI3-kinase. An agonist is provided which stimulates the phosphorylation of the p85 subunit at the serine residue at position 608, wherein phosphorylation at the serine residue indirectly results in inhibiting PI3-kinase activity.

28 Claims, 56 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Generate Collection

Terms

Documents

15 and screen

16

Display 10 Documents

including document number

11

Display Format:

REV

Change Format

Main Menu	Search Form	Posting Counts	Show S Numbers	Edit S Numbers
-----------	-------------	----------------	----------------	----------------

Help	Logout
------	--------

WEST[Help](#)[Logout](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Generate Collection](#)**Search Results - Record(s) 11 through 16 of 16 returned.**☐ 11. Document ID: US 5721266 A

Entry 11 of 16

File: USPT

Feb 24, 1998

US-PAT-NO: 5721266

DOCUMENT-IDENTIFIER: US 5721266 A

TITLE: Substituted imidazoliny-1-imidazolines as antagonists of SH-2 binding and therapeutic uses thereof

DATE-ISSUED: February 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Decker; Stuart James	Ann Arbor	MI	N/A	N/A
Fry; David William	Ypsilanti	MI	N/A	N/A
Hamby; James Marino	Ann Arbor	MI	N/A	N/A
Saltiel; Alan Robert	Ann Arbor	MI	N/A	N/A

US-CL-CURRENT: [514/398](#); [514/400](#), [514/401](#), [514/402](#)

ABSTRACT:

Methods of treating proliferative diseases or viral, inflammatory, allergic and cardiovascular diseases, and restenosis are disclosed. The present invention demonstrates the use of

N,N'-piperazinylbis-[2-amino-1-imidazolin-2-yl)-2-imidazolines], 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylene-bis[2-amino-1-(2-imidazolin-2-yl)-2-imidazolines], their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with a substrate regulatory protein. The present invention also demonstrates the use of pharmaceutical compositions employing N,N'-piperazinylbis[2-amino-1-imidazolin-2-yl)-2-imidazolines], 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylenebis-[2-amino-1-(2-imidazolin-2-yl)-2-imidazolines], their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with substrate regulatory protein. The present invention also relates to novel N,N'-piperazinylbis[2-amino-1-imidazolin-2-yl)-2-imidazolines].

11 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KNAC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 12. Document ID: US 5710129 A

Entry 12 of 16

File: USPT

Jan 20, 1998

US-PAT-NO: 5710129
DOCUMENT-IDENTIFIER: US 5710129 A

TITLE: Inhibitors of SH2-mediated processes

DATE-ISSUED: January 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lynch; Berkley A.	Cambridge	MA	N/A	N/A
Weigele; Manfred	Cambridge	MA	N/A	N/A

US-CL-CURRENT: 514/18; 530/330, 560/21, 560/29

ABSTRACT:

This invention relates to compounds of formula: ##STR1## and pharmaceutically acceptable salts thereof, where A is H, R.sup.1, --CO--R.sup.1 or --CO--OR.sup.1 where R.sup.1 is a substituted or unsubstituted alkyl, heteroalkyl, aryl or heteroaryl group and J is H or NO.sub.2. L-forms of the compounds are currently preferred, although D-forms and racemic mixtures are also encompassed by this invention.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 13. Document ID: US 5580979 A

Entry 13 of 16

File: USPT

Dec 3, 1996

US-PAT-NO: 5580979
DOCUMENT-IDENTIFIER: US 5580979 A

TITLE: Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions

DATE-ISSUED: December 3, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bachovchin; William W.	Melrose	MA	N/A	N/A

US-CL-CURRENT: 540/509; 540/505, 540/510, 540/511, 540/542, 540/569, 540/570, 540/571 , 540/572

ABSTRACT:

The present invention makes available novel compounds represented by the general formula ##STR1## wherein Y represents a phosphate analog. Which compounds are useful for inhibiting an interaction between a protein containing an SH2 domain and a phosphotyrosine-containing polypeptide.

8 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 14. Document ID: US 5573935 A

Entry 14 of 16

File: USPT

Nov 12, 1996

US-PAT-NO: 5573935
DOCUMENT-IDENTIFIER: US 5573935 A

TITLE: Protein tyrosine kinase A6

DATE-ISSUED: November 12, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beeler; John F.	Bethesda	MD	N/A	N/A
Larochelle; William	Gaithersburg	MD	N/A	N/A
Aaronson; Stuart A.	Great Falls	VA	N/A	N/A

US-CL-CURRENT: 435/194; 435/252.3, 435/252.33, 435/320.1, 435/69.8, 536/23.2,
536/23.5, 930/240

ABSTRACT:

A novel protein tyrosine kinase (A6) exhibiting no significant similarity to any known kinase. This protein is widely expressed throughout the body and is present in a variety of vertebrates. The cDNA was expressed in bacteria as a fusion protein which was both autophosphorylated and exhibited kinase activity toward exogenous substrates. Potential uses of this invention include immunodiagnostics and antiproliferative therapeutics.

10 Claims, 1 Drawing figures

Exemplary Claim Number: 1,9

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 15. Document ID: US 5536636 A

Entry 15 of 16

File: USPT

Jul 16, 1996

US-PAT-NO: 5536636
DOCUMENT-IDENTIFIER: US 5536636 A

TITLE: Methods for identifying a tyrosine phosphatase abnormality associated with neoplastic disease

DATE-ISSUED: July 16, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freeman, Jr.; Robert M.	Boston	MA	N/A	N/A
Plutzky; Jorge	Boston	MA	N/A	N/A
Neel; Benjamin G.	Wayland	MA	N/A	N/A
Rosenberg; Robert D.	Brookline	MA	N/A	N/A

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 536/24.3, 536/24.31

ABSTRACT:

The present invention relates to the isolation of genes encoding novel protein tyrosine phosphatases (PTPs) having SH2 domains, the nucleic acid sequences isolated, and the encoded phosphatases. The invention further relates to methods of altering tyrosine phosphatase activities encoded by the novel phosphatases. By altering (i.e., increasing or decreasing) tyrosine phosphatase activity, one can alter megakaryocyte cell function, and thereby alter platelet production. Alteration of the genes is associated with neoplastic disease.

8 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 16. Document ID: US 5529925 A

Entry 16 of 16

File: USPT

Jun 25, 1996

US-PAT-NO: 5529925

DOCUMENT-IDENTIFIER: US 5529925 A

TITLE: Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma

DATE-ISSUED: June 25, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morris; Stephan W.	Memphis	TN	N/A	N/A
Look; A. Thomas	Memphis	TN	N/A	N/A

US-CL-CURRENT: 435/252.3; 435/194, 435/320.1, 536/23.2

ABSTRACT:

The present invention is based on the identification and sequence determination of fusion proteins generated by translocation which is present in t(2;5) lymphoma cells. Using either the amino acid or nucleic acid sequences of the fusion proteins disclosed herein, the present invention provides methods of detecting and treating t(2;5) lymphoma.

5 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

[Generate Collection](#)

Terms	Documents
15 and screen	16

[Display 10 Documents](#)

including document number

[16](#)**Display Format:**[REV](#)[Change Format](#)

Main Menu	Search Form	Posting Counts	Show S Numbers	Edit S Numbers
---------------------------	-----------------------------	--------------------------------	--------------------------------	--------------------------------

[Help](#)[Logout](#)

09/355,204

WEST

Help

Logout

Main Menu

Search Form

Posting Counts

Show 8 Numbers

Edit 8 Numbers

Search Results -

Terms	Documents
l1 and bcr	5

Database: All Databases (USPT + EPAB + JPAB + DWPI + TDBD)

Refine Search:

l1 and bcr

Search History

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
ALL	l1 and bcr	5	<u>L14</u>
ALL	l12 not l11	1	<u>L13</u>
ALL	l2 and bcr	3	<u>L12</u>
ALL	l4 and bcr	2	<u>L11</u>
ALL	l8 not l9	54	<u>L10</u>
ALL	l8 and (grb or plc)	11	<u>L9</u>
ALL	l5 and b adj cell	65	<u>L8</u>
ALL	@py<1997 and l5	7	<u>L7</u>
ALL	l5@py<1997	4294967295	<u>L6</u>
ALL	l4 and signal\$	65	<u>L5</u>
ALL	l2 and tyrosine adj phosphorylat\$	66	<u>L4</u>
ALL	l2 and tyrosine	181	<u>L3</u>
ALL	l1 and B adj cell	297	<u>L2</u>
ALL	receptor and drug same screen	1416	<u>L1</u>

WEST[Help](#)[Logout](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)**Search Results - Record(s) 1 through 5 of 5 returned.****1. Document ID: US 6011137 A**

Entry 1 of 5

File: USPT

Jan 4, 2000

US-PAT-NO: 6011137

DOCUMENT-IDENTIFIER: US 6011137 A

TITLE: Identification and isolation of novel polypeptides having WW domains and methods of using same

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pirozzi; Gregorio	East Windsor	NJ	N/A	N/A
Kay; Brian K.	Chapel Hill	NC	N/A	N/A
Fowlkes; Dana M.	Chapel Hill	NC	N/A	N/A

US-CL-CURRENT: 530/324; 435/69.7, 435/7.1, 435/810, 435/975, 530/350

ABSTRACT:

Novel polypeptides having WW domains of interest are described, along with DNA sequences that encode the same. A method of identifying these polypeptides by means of a sequence-independent (that is, independent of the primary sequence of the polypeptide sought), recognition unit-based functional screen is also disclosed. Various applications of the method and of the polypeptides identified are described, including their use in assay kits for drug discovery, modification, and refinement.

5 Claims, 23 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

2. Document ID: US 5925523 A

Entry 2 of 5

File: USPT

Jul 20, 1999

US-PAT-NO: 5925523
DOCUMENT-IDENTIFIER: US 5925523 A

TITLE: Intraction trap assay, reagents and uses thereof

DATE-ISSUED: July 20, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dove; Simon	Cambridge	MA	N/A	N/A
Joung; J. Keith	Winchester	MA	N/A	N/A
Hochschild; Ann	Brookline	MA	N/A	N/A

US-CL-CURRENT: 435/6; 435/29

ABSTRACT:

The present invention makes available an interaction trap system (hereinafter "ITS") which is derived using recombinantly engineered prokaryotic cells.
36 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

3. Document ID: US 5849553 A

Entry 3 of 5

File: USPT

Dec 15, 1998

US-PAT-NO: 5849553
DOCUMENT-IDENTIFIER: US 5849553 A

TITLE: Mammalian multipotent neural stem cells

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Anderson; David J.	Altadena	CA	N/A	N/A
Stemple; Derek L.	Newton	MA	N/A	N/A

US-CL-CURRENT: 435/467; 435/320.1, 435/325, 435/353, 435/368, 435/455, 435/462, 435/69.1

ABSTRACT:

The invention includes mammalian multipotent neural stem cells and their progeny and methods for the isolation and clonal propagation of such cells. At the clonal level the stem cells are capable of self regeneration and asymmetrical division. Lineage restriction is demonstrated within developing clones which are sensitive to the local environment. The invention also includes such cells which are transfected with foreign nucleic acid, e.g., to produce an immortalized neural stem cell, and immortalized cell lines which are capable of subsequent disimmortalization. The invention further includes transplantation assays which allow for the identification of mammalian multipotent neural stem cells from various tissues and methods for transplanting mammalian neural stem cells and/or neural or glial progenitors into mammals. A novel method for detecting antibodies to neural cell surface markers is disclosed as well as a monoclonal antibody to mouse LNGFR.

25 Claims, 111 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

4. Document ID: US 5807671 A

Entry 4 of 5

File: USPT

Sep 15, 1998

US-PAT-NO: 5807671

DOCUMENT-IDENTIFIER: US 5807671 A

TITLE: Method of screening for genetic predisposition to anticholinesterase therapy

DATE-ISSUED: September 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Soreq; Hermona	Rishon le Zion	N/A	N/A	ILX
Zakut; Haim	Savyon	N/A	N/A	ILX

US-CL-CURRENT: 435/6; 435/19, 435/7.1, 436/518

ABSTRACT:

A method of screening for a genetic predisposition to anticholinesterase exposure. The method includes the steps of obtaining a peripheral blood sample, and then analysing serum from the blood sample for BuChE levels and inhibitor-susceptibilities. The DNA of peripheral white blood cells from the blood sample is also screened for the presence of BuChE alleles thereby identifying patients who have a genetic predisposition to anticholinesterase exposure.

2 Claims, 37 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

5. Document ID: US 5770421 A

Entry 5 of 5

File: USPT

Jun 23, 1998

US-PAT-NO: 5770421

DOCUMENT-IDENTIFIER: US 5770421 A

TITLE: Human ALK protein tyrosine kinase

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morris; Stephan W.	Memphis	TN	N/A	N/A
Look; A. Thomas	Memphis	TN	N/A	N/A

US-CL-CURRENT: 435/194; 530/324, 530/350, 530/352, 530/358

ABSTRACT:

The present invention is based on the identification and sequence determination of a novel gene, ALK, which is fused to the gene encoding nucleophosmin (NPM) in translocations present in t(2;5) lymphoma cells. Based on homologies to other proteins, the amino acid sequence of the polypeptide encoded by the ALK (Anaplastic Lymphoma Kinase) gene is a membrane-spanning protein tyrosine kinase (PTK)/receptor. Antibodies to the ALK PTK/receptor and methods utilizing such antibodies are described, as are methods of using the ALK gene to isolate ligands for the ALK PTK/receptor.

12 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Terms	Documents
11 and bcr	5

including document number

Display Format:
